Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Tolerability and efficacy… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: A double-blind cross-over study

Artikel i vetenskaplig tidskrift
Författare A. Kloberg
Radu Constantinescu
Marie Nilsson
Maria L. Carlsson
Arvid Carlsson
Jan Wahlström
Sara Haghighi
Publicerad i Acta Neuropsychiatrica
Volym 26
Nummer/häfte 5
Sidor 298-306
ISSN 0924-2708
Förlag Cambridge University Press
Publiceringsår 2014
Publicerad vid Institutionen för biomedicin, avdelningen för medicinsk genetik och klinisk genetik
Institutionen för neurovetenskap och fysiologi
Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering
Sidor 298-306
Språk en
Länkar dx.doi.org/10.1017/neu.2014.16
Ämnesord depression, huntington's disease, monoaminergic stabilizer, vitality, 3 [3 (methylsulfonyl)phenyl] 1 propylpiperidine, absence of side effects, adult, Article, Beck Depression Inventory, clinical article, cognition, controlled study, crossover procedure, double blind procedure, drug efficacy, drug tolerability, female, human, Huntington chorea, male, mental function, mood, motor performance, quality of life, randomized controlled trial, rating scale, Short Form 36, social status, symptomatology
Ämneskategorier Klinisk medicin

Sammanfattning

Objective To evaluate the safety (primary objective) and efficacy (secondary objective) of (-)-OSU6162 in Huntington's disease (HD). Methods In a double-blind, cross-over trial, patients with HD were randomly assigned to start treatment on either (-)-OSU6162 or placebo. After 4 weeks, those patients who initially received active drug were switched to placebo for another 4 weeks, and vice versa. During the first week the (-)-OSU6162 dose was 15 mg twice daily, during the second week 30 mg twice daily, and during the last 2 weeks 45 mg twice daily. Motor, cognitive, mental and social functions were rated by the clinical investigator or by self-assessment, using established rating scales. Results Fifteen patients fulfilling inclusion and exclusion criteria completed the study. (-)-OSU6162 was well tolerated by all patients and no adverse effects were observed. (-)-OSU6162 treatment significantly improved the Short Form 36 Vitality score, mainly due to an improvement of the individual item 'worn-out' (VT3). In addition, an improvement of depressive symptoms was found using Beck Depression Inventory. In contrast to a general trend of improvement in several non-motor variables only small and non-significant differences between (-)-OSU6162 and placebo were found regarding motor functions. Conclusions (-)-OSU6162 offers promise for the treatment of HD, as a drug with good tolerability, capable of improving the patients' experienced non-motor functions such as energy and mood and thus alleviating symptoms of great importance for their quality of life. © © Scandinavian College of Neuropsychopharmacology 2014.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?